Protagonist Therapeutics Inc PTGX:NASDAQ

Last Price$28.42NASDAQ Previous Close - Last Trade as of 3:57PM ET 1/26/22

Today's Change-0.38(1.32%)
Bid (Size)$13.01 (1)
Ask (Size)$39.99 (1)
Day Low / High$28.00 - 30.34
Volume635.0 K
 

View Biotechnology IndustryPeer Comparison as of 01/26/2022

 

Protagonist Therapeutics Inc ( NASDAQ )

Price: $28.42
Change: -0.38 (1.32%)
Volume: 635.0 K
3:57PM ET 1/26/2022
 
 

Celldex Therapeutics Inc ( NASDAQ )

Price: $28.88
Change: +0.04 (0.14%)
Volume: 640.1 K
3:59PM ET 1/26/2022
 
 

FibroGen Inc ( NASDAQ )

Price: $14.50
Change: +0.07 (0.49%)
Volume: 1.1 M
3:57PM ET 1/26/2022
 
 

Atara Biotherapeutics Inc ( NASDAQ )

Price: $15.25
Change: +0.15 (0.99%)
Volume: 940.0 K
3:57PM ET 1/26/2022
 
 

Iveric Bio Inc ( NASDAQ )

Price: $13.01
Change: +0.11 (0.85%)
Volume: 1.4 M
3:57PM ET 1/26/2022
 

Read more news Recent News

Insider Sell: Protagonist Therapeutics
5:22PM ET 12/23/2021 MT Newswires

Dinesh V Patel, Director, President and CEO, on December 21, 2021, sold 15,000 shares in Protagonist Therapeutics (PTGX) for $482,171. Following the Form 4...

Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
5:26PM ET 12/02/2021 MT Newswires

Protagonist Therapeutics (PTGX) said Thursday it has chosen PN-235 as the final candidate for all clinical studies in multiple indications as part of its...

Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditary Hemochromatosis Treatment
11:05AM ET 11/15/2021 MT Newswires

Protagonist Therapeutics (PTGX) said Monday that results from a study to evaluate rusfertide as an investigational drug to treat hereditary...

--JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps Market Outperform Rating
9:05AM ET 11/15/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
3:02PM ET 1/11/2022 Seeking Alpha

Protagonist Therapeutics (PTGX) Investor Presentation - Slideshow
3:23PM ET 12/09/2021 Seeking Alpha

Wall Street Breakfast: What Moved Markets
7:47AM ET 10/16/2021 Seeking Alpha

Protagonist Therapeutics: How To Buy The Dip
6:14PM ET 9/30/2021 Seeking Alpha

Company Profile

Business DescriptionProtagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. View company web site for more details
Address7707 Gateway Boulevard
Newark, California 94560-1160
Phone+1.510.474.0170
Number of Employees64
Recent SEC Filing12/23/20214
President, Chief Executive Officer & DirectorDinesh V. Patel
Chief Financial OfficerDonald A. Kalkofen
Vice President-TechnologyMark L. Smythe
Chief Scientific OfficerDavid Y. Liu

Company Highlights

Price Open$29.28
Previous Close$28.42
52 Week Range$12.80 - 50.54
Market Capitalization$1.4 B
Shares Outstanding47.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.41
Beta vs. S&P 500N/A
Revenue$30.9 M
Net Profit Margin-440.88%
Return on Equity-35.08%

Analyst Ratings as of 10/11/2021

Buy
7
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset